^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    24h
    CR108485: A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (clinicaltrials.gov)
    P1, N=114, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    onametostat (JNJ-64619178)
    1d
    EPCOR+LONCA: Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=26, Recruiting, University of Miami | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epkinly (epcoritamab-bysp) • Zynlonta (loncastuximab tesirine-lpyl)
    1d
    ES FLIT Registry: Evaluate the use of Early-Stage Follicular Lymphoma International ImmunoTherapy Registry and initial analysis plan to describe progression-free survival for patients with stage I-II follicular lymphoma treated with radiotherapy alone compared with radiotherapy plus immunotherapy. (ACTRN12624000669594)
    P=N/A, N=500, Recruiting, Peter MacCallum Cancer Centre | N=300 --> 500
    Enrollment change
    1d
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision
    Trial completion date • Trial termination
    |
    CD19 positive
    |
    CNTY-101
    1d
    P13 The cellulitis that wasn't: a case of subcutaneous panniculitis-like T-cell lymphoma in a toddler. (PubMed, Br J Dermatol)
    Treatment with high-dose prednisolone and ciclosporin led to complete remission...SPTCL should be considered in children with panniculitis nodules unresponsive to antibiotics, but distinction from lupus erythematosus profundus and infection remains a critical diagnostic pitfall. Accurate diagnosis and management require multidisciplinary input, highlighting the importance of an MDT approach in such complex paediatric cases.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cyclosporine
    1d
    Empagliflozin beyond antidiabetic effect: Amelioration of cyclophosphamide-induced testicular toxicity in rats: Orchestrating klotho/Nrf-2/PPAR-γ/NF-κB/ Bax/Bcl-2 cues. (PubMed, Biochem Pharmacol)
    Furthermore, EMPA enhanced testicular tissue survival by decreasing Bcl-2-associated X (Bax) protein, while elevating B-cell lymphoma 2 (Bcl-2) protein, thus reducing caspase-3 expression. Consequentially, EMPA, through antioxidant, anti-inflammatory, and anti-apoptotic effects, could be nominated as a promising candidate against CP-induced gonadal toxicity.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    cyclophosphamide
    1d
    Formononetin protects against oxaliplatin-induced peripheral neurotoxicity via Nrf2/HO-1 antioxidant pathway without impairing anticancer efficacy. (PubMed, Neurotoxicology)
    Importantly, unlike the ROS scavenger N-acetylcysteine (NAC), which decreased the anticancer effectiveness of both oxaliplatin and paclitaxel, formononetin maintained their anticancer effects in colorectal cancer HT29 cells and cervical cancer SiHa cells. Taken together, formononetin holds potential as a neuroprotectant to prevent oxaliplatin-induced neurotoxicity without compromising anticancer efficacy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1)
    |
    paclitaxel • oxaliplatin
    1d
    Hematologic Focal Hepatic Lesions in the Absence of Liver Cirrhosis: Consider Lymphoma and Myeloma. (PubMed, Clin Res Hepatol Gastroenterol)
    In patients with solitary liver lesions, normal tumor markers, and no chronic liver disease, clinicians should maintain a high index of suspicion for hematologic malignancies. Accurate imaging assessment and tissue diagnosis are essential for optimal treatment planning.
    Review • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    1d
    Celastrol induces cardiotoxicity by directly targeting AMOTL2 and inhibiting YAP1/PGC-1α/TFAM-dependent mitochondrial biogenesis. (PubMed, Chem Biol Interact)
    Knockdown of AMOTL2 by short hairpin RNA attenuated celastrol-induced cardiomyocyte apoptosis by enhancing YAP1 expression and mitochondrial biogenesis. These findings demonstrate that celastrol induces cardiotoxicity by directly targeting AMOTL2 and disrupting YAP1/PGC-1α/TFAM-dependent mitochondrial biogenesis.
    Journal • IO biomarker
    |
    YAP1 (Yes associated protein 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TFAM (Transcription Factor A, Mitochondrial)
    1d
    SURGE: Survivors Uniting for Remote Guided Exercise (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Colorado State University
    New trial
    1d
    ECHELON-3: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P3, N=238, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Adcetris (brentuximab vedotin)
    1d
    Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, University of Nebraska
    New P2 trial